title: [Case of acute kidney injury related to intravenous zoledronic acid in a patient with multiple myeloma].
abstract: We report the first case of acute kidney injury related to intravenous zoledronic acid (ZA)in a patient with multiple myeloma in Japan. A 37-year-old male was diagnosed as having multiple myeloma (MM) of the Bence Jones lambda type. He showed a good response to two courses of vincristine, adriamycin and dexamethasone (VAD) therapy, and remarkable reduction was seen in plasma cells in bone marrow from 38.4% to 6.8% and 24-hour urine protein from 18.5 g/dL to 2.8 g/dL. At that time, serum Cr(s-Cr) of 0.7 mg/dL and calcium of 9.3 mg/dL were in the normal range. ZA was administered intravenously at the dose of 4 mg for the first time. Subsequently, he developed a fever of up to 39.4 degrees C and used NSAIDs and cefepime. Four days later, s-Cr increasd rapidly to 7.3 mg/ dL and he received hemodialysis (HD) therapy. Four weeks later, renal biopsy was performed and demonstrated cast nephropathy (CN) and acute tubular necrosis. Seven months later, renal function had improved. ZA may be an identifiable precipitating factor of CN. We recommend that ZA should be used with caution, especially hypovolemia and NSAIDs, in patients with MM and renal insufficiency.
authors.affiliation: Division of Nephrology, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan.
authors.forename: Kiyomi
authors.initials: K
authors.lastname: Koike
authors.forename: Kei
authors.initials: K
authors.lastname: Fukami
authors.forename: Satoshi
authors.initials: S
authors.lastname: Morishige
authors.forename: Takuma
authors.initials: T
authors.lastname: Hazama
authors.forename: Kensei
authors.initials: K
authors.lastname: Taguchi
authors.forename: Ryotaro
authors.initials: R
authors.lastname: Ando
authors.forename: Makio
authors.initials: M
authors.lastname: Nagano
authors.forename: Junko
authors.initials: J
authors.lastname: Yoshimura
authors.forename: Seiji
authors.initials: S
authors.lastname: Ueda
authors.forename: Michitoshi
authors.initials: M
authors.lastname: Hashiguchi
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Tamaki
authors.forename: Hidemi
authors.initials: H
authors.lastname: Nishida
authors.forename: Seiya
authors.initials: S
authors.lastname: Okuda
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced* / Q000628:therapy; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001847:Bone Diseases / Q000188:drug therapy* / Q000209:etiology; D003907:Dexamethasone / Q000008:administration & dosage; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects*; D007275:Injections, Intravenous; D008297:Male; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy; D006435:Renal Dialysis; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D014750:Vincristine; D000077211:Zoledronic Acid; D003907:Dexamethasone; D004317:Doxorubicin